The combination of pembrolizumab (Keytruda), and lenvatinib (Lenvima) demonstrated promising clinical activity with no unexpected toxicities in patients with malignant pleural mesothelioma (MPM), according to results from the PEMMELA study (NCT04287829) presented at the International Association for the Study of Lung Cancer 2022 World … [Read more...]
Keytruda / Opdivo / Yervoy: May Cause Vision Loss, Retinal Detachment
A developing drug safety issue is presented in this news report, “FDA Considers Label Changes for Keytruda, Opdivo and Yervoy”, which was posted July 12, 2017 on the Regulatory Affairs Professional Society (RAPS) website. Here are some contextual details provided by reporter Zachary Brennan in this article: The consideration for changing the … [Read more...]